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Abstract The 5P-flanking sequences of the human macrophage
inflammatory protein-3K/CCL20 gene were cloned and trans-
fected into G-361 human melanoma cells in a luciferase reporter
construct. Tumor necrosis factor-K (TNF-K) treatment stimu-
lated luciferase expression, and promoter truncations demon-
strated that TNF-K inducibility is conferred by a region between
nt 3111 and 377, which contains a non-standard nuclear factor-
UB (NF-UB) binding site. The requirement for NF-UB was
demonstrated as follows: (i) mutations in this NF-UB site
abrogated TNF-K responsiveness ; (ii) TNF-K activated a
construct containing two copies of the CCL20 NF-UB binding
site; (iii) overexpression of NF-UB p65 activated the CCL20
promoter ; (iv) NF-UB from nuclear extracts of TNF-K-
stimulated cells bound specifically to this NF-UB site. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Chemokines comprise a large group of closely related pro-
teins which play important roles in in£ammation and immune
response regulation. Due to a conserved pair of cysteine res-
idues, chemokines are subdivided into two main groups, the
CC and CXC chemokines. Other chemokine subfamilies have
also been identi¢ed, the C and CX3C chemokines. Chemo-
kines can attract various di¡erent cell types, including e¡ector
cells, into areas of in£ammation. They also regulate immune
homeostasis by coordinating lymphocyte and dendritic cell
(DC) tra⁄cking, and are involved in the regulation of hema-
topoiesis and angiogenesis [1,2].
Human macrophage in£ammatory protein-3K (MIP-3K)/
CCL20 [3], also called liver and activation-induced chemokine
(LARC) [4], Exodus [5] or SCYA20, is a CC chemokine which
attracts memory T lymphocytes and immature DCs [6^9].
CCL20 binds to the chemokine receptor CCR6, which is ex-
pressed on immature DCs and memory T lymphocytes, but is
also found on B lymphocytes [10^17]. CCL20 mRNA is
highly expressed in lung, liver and in£amed tissues, such as
tonsil, appendix and lesional psoriatic skin [3^5,7,10]. The
cellular source of CCL20 is mainly of epithelial origin, such
as keratinocytes, but it is also expressed by other cell types,
including endothelial cells, ¢broblasts, and monocytes [3^
5,7,18,19]. CCL20 is released upon stimulation of cells with
various pro-in£ammatory cytokines, such as interleukin-1 (IL-
1), tumor necrosis factor-K (TNF-K), IL-17 and interferon-Q
(IFN-Q), but also by other stimuli, including lipopolysaccha-
ride, 12-O-tetradecanoylphorbol-13-acetate (PMA) and viral
infection [7,18].
The mechanism by which CCL20 expression is regulated by
pro-in£ammatory cytokines such as TNF-K has not been an-
alyzed in detail so far, although evidence exists for both tran-
scriptional and post-transcriptional regulation [18,20]. How-
ever, TNF-K is known to frequently act via the transcription
factor nuclear factor-UB (NF-UB), which is therefore likely to
be involved in regulation of CCL20 expression [20]. NF-UB is
a transcription factor complex containing the proteins p50
(NF-UB1), p52 (NF-UB2), p65 (RelA), c-Rel and RelB [21].
Various homo- or heterodimers can bind to NF-UB recogni-
tion sites located in regulatory regions of many genes, but the
most common complex is the p50/p65 heterodimer. Activation
of NF-UB is associated with phosphorylation and proteolytic
degradation of the inhibitory protein IUB through activation
of the IUB kinase complex [22,23]. Since NF-UB plays a piv-
otal role in in£ammatory and immune responses, we investi-
gated whether this transcription factor is involved in regula-
tion of CCL20 expression. We have cloned and functionally
characterized the CCL20 promoter, and show that stimulation
with TNF-K can cause NF-UB-dependent activation of the
CCL20 promoter and have further identi¢ed an element
which is bound and activated by NF-UB.
2. Materials and methods
2.1. Reagents
Recombinant human TNF-K was purchased from Genzyme. For
experiments using HT-29 cells, recombinant human TNF-K from
RpD Systems was used.
2.2. Plasmids
The 5P-£anking region of the human CCL20 gene (nt 3626 to +58
relative to the transcription start) was cloned by PCR from human
genomic DNA isolated from human peripheral blood leukocytes. The
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primers were designed according to the genomic sequence using the
primer (sense) 5P-CATCATCATGGTACCAAATCAAGGTGAAG-
CTGAGGTTTGAGC-3P and the primer (antisense) 5P-CATCAT-
CATCTCGAGGGTTTTTAGCTCAAAGAACAGATCTGC-3P (re-
striction sites for cloning are underlined). The ampli¢ed PCR
product was digested with KpnI and XhoI and cloned into the KpnI
and XhoI sites of the pGL2-basic vector (Promega). Serial 5P-trunca-
tions of the CCL20 promoter were created by PCR using the original
fragment as template. The following primers were used: primer 5P-
CATCATGGTACCTGTGTGGGGCTGACC-3P (S4: nt 3358 to
+58 relative to the transcription start); primer 5P-CATCATGG-
TACCGGATGAAAGTCTTTTCTG-3P (S5: nt 3288 to +58 relative
to the transcription start); primer 5P-CATCATGGTACCTGGGGC-
CAGTTGATC-3P (S6: nt 3111 to +58 relative to the transcription
start) and primer 5P-CATCATGGTACCGGCAACACGCCTTCTG-
3P (S7: nt 377 to +58 relative to the transcription start). These prim-
ers were used in combination with the antisense primer for ampli¢ca-
tion. The fragments were subcloned into the KpnI and XhoI sites of
the pGL2-basic vector. The truncated interleukin-8 (IL-8) promoter-
luciferase construct (nt 3101 to +40 relative to the transcription start)
has been described previously [24].
For introduction of mutations into the putative CCL20 NF-UB
binding site primer 5P-CATCATGGTACCTGGGGCCAGTTGAT-
CAATGGGGAAggggCCATG-3P was used (mutated nucleotides are
written in small letters). To alter the putative CCL20 NF-UB binding
site into the NF-UB binding site of the IL-8 promoter, the following
primer was used: 5P-CATCATGGTACCTGGGGCCAGTTGAT-
CAATGGGGAATTTCCCATG-3P (the IL-8 NF-UB binding site is
written in bold).
These primers were used in combination with the antisense primer
for ampli¢cation and fragments were cloned into the KpnI and XhoI
sites of pGL2-basic vector.
The construct tkLUC contains 155 bp of the thymidine kinase (tk)
promoter of the herpes simplex virus I cloned into pGL2-basic vector
[25]. The construct 2U(CCL20)NF-UB tkLUC contains two copies of
the sequence CCL20-NF-UB: 5P-GATCAATGGGGAAAACCCCA-
TGTGGCAACACG-3P upstream of tkLUC in pGL2-basic vector.
The construct pRL-tk was constructed by cloning the 155 bp of the
tk promoter into the BglII and HindIII sites of the pRL-basic vector
(Promega). All constructs were con¢rmed by sequencing.
The pRcCMV-p65 expression plasmid was kindly provided by W.C.
Greene (Gladstone Institute of Virology and Immunology, San Fran-
cisco, CA, USA).
2.3. Cell culture, transient transfections and luciferase assays
The human melanoma cell line G-361 was cultivated in minimal
essential medium+5% fetal calf serum (FCS) and passaged twice per
week. Transfections were performed as described previously [24]. Lu-
ciferase activity in cell lysates was determined using the luciferase
assay system (Promega) and recorded in a Microbeta Wallac Jet lu-
minometer.
The human embryonic kidney cell line HEK293 was cultivated in
RPMI 1640 supplemented with 10% FCS. For transfections 2.4U105
cells were seeded into each well of a six well plate and transfected with
1.7 Wg reporter gene construct, 0.34 Wg pcDNA3.1 vector or p65
expression plasmid together with 100 ng pRL-tk and 1.7 Wl lipofect-
amine for 5 h at 37‡C in FCS-free RPMI. For assaying ¢re£y and
renilla luciferase expression in the same samples, the dual luciferase
assay system (Promega) was used.
The human colon adenocarcinoma cell line HT-29 was cultivated in
Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% FCS.
2.4. Reverse transcription-PCR (RT-PCR)
RT-PCR was performed according to standard protocols. For am-
pli¢cation the following primers were used: CCL20 sense: 5P-
GAACTGGGTACTCAACACTGAGCAG-3P, CCL20 antisense: 5P-
TTTACTGAGGAGACGCAC-3P, IL-8 sense: 5P-ATGACTTCCAA-
GCTGGCCGTGGCT-3P, IL-8 antisense: 5P-TCTCAGCCCTCTT-
CAAAAACTTCTC-3P, L-actin sense: 5P-ATGGGTCAGAAGGA-
TTCCTATGTG-3P, L-actin antisense: 5P-CTTCATGAGGTAGTC-
AGTCAGGTC-3P.
PCR was performed at 94‡C for 2 min for denaturation, then 94‡C
for 20 s, 58‡C for 20 s, 72‡C for 30 s (for detection of CCL20 and
IL-8 cDNAs 38 cycles and for detection of L-actin 30 cycles were
performed) and a ¢nal extension at 72‡C for 5 min using a Perkin-
Elmer 9700 thermal cycler.
2.5. Electrophoretic mobility shift assays (EMSAs)
Nuclear extracts and EMSA experiments were prepared from G-
361 cells and HT-29 cells as described previously [24]. For EMSA
experiments, the following oligonucleotides were used: CCL20-
NF-UB: 5P-GATCAATGGGGAAAACCCCATGTGGCAACACG-
3P, CCL20-NF-UB mut: 5P-GATCAATGGGGAAggggCCATGTGG-
CAACACG-3P, HIV NF-UB: 5P-GATCTTGTTACAAGGGACTT-
TCCGCG-3P.
For supershift analysis, goat anti-p50 and rabbit anti-p65 (Santa
Cruz) were used. 2 Wl of each antibody was used per sample in EMSA
analysis.
3. Results
3.1. Cloning of the 5P-£anking sequences of the CCL20 gene
and functional characterization in G-361 cells
Expression of CCL20 has been shown to be induced by
various pro-in£ammatory cytokines, such as IL-1, TNF-K,
IFN-Q and IL-17 [7,18] and stimuli such as PMA [4] and viral
infection [19] in various cell lines and primary cells. Some cell
lines respond to combinations of cytokines, such as IL-1 and
TNF-K, or TNF-K and IL-17, by synergistic enhancement of
CCL20 expression [7,18]. Since little is known about the tran-
scriptional regulation of this chemokine, we cloned the 5P-
£anking sequences of the CCL20 gene and analyzed the e¡ect
of TNF-K on activation of the CCL20 promoter.
The genomic sequence of the CCL20 gene is now available
in Ensembl (clones AC027560 and AC073065). Meanwhile,
the genomic structure of the CCL20 gene was also published
by Nelson et al. [26]. We analyzed the 5P-£anking region of
the CCL20 gene for potential transcription factor binding
sites and demonstrate the presence of a putative TATA- and
CAAT-box, as well as potential binding sites for various tran-
scription factors, including NF-UB (Fig. 1). Nelson et al. sug-
gested the transcription start to be located 81 bases upstream
of the initiating AUG on the basis of the promoter analysis
program Proscan [26]. However, Hieshima et al. analyzed the
transcription start by 3P-rapid ampli¢cation of cDNA ends
PCR using RNA derived from PMA-stimulated U937 cells
and screening of a cDNA library from human liver. They
indicated the transcription start to be located 58 bp upstream
of the start codon AUG [4], which we have adopted for the
current study. We cloned the CCL20 promoter by PCR from
human genomic DNA and subcloned the PCR fragment into
the pGL2-basic vector, to drive expression of the ¢re£y lucif-
erase coding region.
For transient transfection experiments we chose the human
melanoma cell line G-361, which has been utilized by us in the
past for transient transfection experiments using the IL-8 pro-
moter, driving NF-UB-dependent reporter gene expression
[24,25]. Although levels of endogenous CCL20 produced by
G-361 cells are very low (data not shown), this cell line has
proven to be useful for promoter analysis and responds well
to stimulation with TNF-K.
The CCL20 promoter (nt 3626 to +58)-luciferase construct
was transiently transfected into the human melanoma cell line
G-361. Stimulation of transfected cells with TNF-K (200 U/
ml) for 24 h resulted in a 6-fold enhancement of luciferase
activity. Various 5P-truncations of the promoter were con-
structed and cloned into the pGL2-basic vector. The trun-
cated CCL20 promoter constructs S4 (nt 3358 to +58), S5
(nt 3288 to +58) and S6 (nt 3111 to +58) were transiently
transfected into G-361 cells. Stimulation of transfected cells
with TNF-K (200 U/ml) for 24 h resulted in a 6^10-fold stim-
FEBS 25526 10-12-01
H. Harant et al./FEBS Letters 509 (2001) 439^445440
ulation of luciferase activity (Fig. 2a). The activation of the
CCL20 promoter reporter gene constructs by TNF-K was
compared with that of a truncated IL-8 promoter (3101 to
+40)-luciferase construct, which contains a functional NF-UB
binding site and is activated in G-361 cells. TNF-K induces a
25-fold activation of the IL-8 promoter, which was higher
compared to the 6-fold activation of the short CCL20 pro-
moter construct S6 (Fig. 2a).
When a further 34 bp were removed from the 5P-end of the
short CCL20 promoter construct S6 (nt 3111 to +58) result-
ing in construct S7 (nt 377 to +58), the TNF-K inducibility
was abrogated, indicating the presence of regulatory sequen-
ces within this region (Fig. 2a). Analysis of the CCL20 pro-
moter sequence showed that the sequence 5P-
GGGGAAAACCCC-3P located between nt 393 and 382
represents a putative binding site for NF-UB. Pro-in£amma-
tory cytokines, such as IL-1 and TNF, are known activators
of NF-UB, which is involved in regulation of various chemo-
kine genes [27]. Regulation of CCL20 expression through ac-
tivation of NF-UB has been suggested by Izadpanah et al.,
who infected the human colon adenocarcinoma cell line HT-
29 with a recombinant adenovirus expressing a mutant IUBK
protein, which acts as a superrepressor of NF-UB activation.
They showed that stimulation of infected cells with di¡erent
in£ammatory stimuli causes a signi¢cant reduction in CCL20
release [20]. To determine whether NF-UB is directly involved
in the activation of the CCL20 promoter by TNF-K, we in-
troduced mutations into the truncated CCL20 promoter (S6,
nt 3111 to +58). We transfected G-361 cells with the con-
struct S6 containing mutations in the putative NF-UB binding
site (CCL20 S6 NF-UB mutated) and saw a loss of responsive-
ness to TNF-K, suggesting that this site does indeed represent
a binding site for NF-UB. In contrast, replacement of the
CCL20 NF-UB binding site by the NF-UB binding site of
the IL-8 promoter (CCL20 S6 NF-UB IL-8) resulted in the
same levels of inducibility by TNF-K as the wild-type con-
struct S6 (Fig. 2b).
Two copies of the element containing the putative NF-UB
binding site were cloned upstream of a 155 bp fragment of the
herpes simplex virus I tk promoter, to determine whether
TNF-K can activate via this site in a di¡erent promoter con-
text. Transfection of G-361 cells with a reporter gene con-
struct containing only the tk promoter (tkLUC) and treat-
ment with TNF-K for 24 h did not enhance luciferase
expression. In contrast, transfection with the construct con-
taining two copies of the CCL20 NF-UB sequences fused to
the tk promoter (2U(CCL20)NF-UB tkLUC) resulted in a 5-
fold induction of luciferase expression after TNF-K treatment
(Fig. 2c).
3.2. The NF-UB subunit p65 (RelA) transactivates the
CCL20 promoter
To analyze whether NF-UB can physically bind and trans-
activate the CCL20 promoter in a di¡erent cell system,
HEK293 cells were cotransfected with various CCL20 pro-
moter constructs together with an expression plasmid for
Fig. 1. Schematic representation of the 5P-£anking sequences of the CCL20 gene. The putative transcription start is marked as +1 and indicated
by an arrow. The start codon ATG at position +59 is written in bold. The TATA-box and other potential binding sites for transcription fac-
tors are underlined.
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the NF-UB subunit p65 (RelA). Cotransfection of p65 togeth-
er with the minimal CCL20 promoter (S6, nt 3111 to +58)
showed a robust 300-fold activation of this promoter by over-
expression of p65. In comparison, overexpression of p65
showed only little activation of the CCL20 construct S7 (nt
377 to +31) which lacks the NF-UB binding site (Fig. 3a).
This minor e¡ect may result from some interference of over-
expressed p65 with the internal control vector pRL-tk.
Similar results were obtained when the p65 expression plas-
mid was cotransfected with 2U(CCL20)NF-UB tkLUC. Over-
expression of p65 resulted in a 50-fold increase in luciferase
activity, but had little e¡ect when cotransfected with tkLUC
(Fig. 3b).
3.3. NF-UB binds to a site located in the CCL20 promoter
Nuclear extracts were prepared from G-361 cells, either un-
Fig. 2. a: The CCL20 promoter is activated by TNF-K in the human melanoma cell line G-361. The CCL20 promoter (nt 3626 to +58 relative
to the transcription start), serial 5P-truncations thereof (S4: nt 3358 to +58; S5: nt 3288 to +58; S6: nt 3111 to +58; S7: nt 377 to +58 rel-
ative to the transcription start) and the truncated IL-8 promoter (nt 3101 to +40 relative to the transcription start) were cloned upstream of
the ¢re£y luciferase coding region into the pGL2-basic vector. Transient transfections of G-361 cells and further 24 h stimulation with recombi-
nant human TNF-K (200 U/ml) were performed. Relative luciferase activities compared to untreated controls are shown as means þ S.D. from
¢ve independent experiments. b: G-361 cells were transiently transfected with the truncated CCL20 promoter construct S6 (nt 3111 to +58),
construct S6 containing a mutated NF-UB binding site (CCL20 S6 NF-UB mutated), or construct S6 containing the NF-UB binding site of the
IL-8 promoter (CCL20 S6 NF-UB IL-8). Relative luciferase activities after a 24 h stimulation with TNF-K compared to untreated controls are
shown as means þ S.D. from eight independent experiments. c: G-361 cells were transiently transfected with either the construct tkLUC or a
construct containing two copies of the CCL20 NF-UB binding site upstream of the tk promoter (2U(CCL20)NF-UB tkLUC) and stimulated
with TNF-K for 24 h. Relative luciferase activities compared to untreated controls are shown as means þ S.D. from ¢ve independent experi-
ments.
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stimulated or stimulated with TNF-K (200 U/ml). EMSAs,
using a radiolabelled oligonucleotide representing the NF-
UB-binding site of the CCL20 promoter, demonstrated the
presence of binding activity in nuclear extracts from TNF-K-
stimulated G-361 cells. Competition experiments using excess
of unlabelled oligonucleotide demonstrated that this binding
activity was speci¢c. When an excess unlabelled oligonucleo-
tide containing mutations in the NF-UB binding site was used,
no competition of the binding complex was seen. However,
the complex was competed by an excess of unlabelled oligo-
nucleotide representing the NF-UB binding site of the HIV
LTR, suggesting that this binding activity is indeed NF-UB.
Supershift analysis using antibodies directed against the NF-
UB subunits p50 and p65 demonstrated that the complex con-
tains both of these proteins (Fig. 4a).
This conclusion was further supported by performing
EMSA analysis with a radiolabelled oligonucleotide represent-
ing the NF-UB binding site of the HIV LTR and nuclear
extracts from TNF-K-stimulated G-361 cells. This complex
migrated at the same speed as the complex formed on the
CCL20 NF-UB binding site and was speci¢cally competed
by excess of the oligonucleotide representing the CCL20
NF-UB binding site but not with the oligonucleotide contain-
ing the mutated CCL20 NF-UB binding site (Fig. 4b).
Similar experiments were performed with nuclear extracts
from TNF-K-stimulated HT-29 cells, which have been ana-
lyzed by Izadpanah et al. for expression of CCL20 expression
[20]. To determine whether CCL20 is regulated in HT-29 cells
under our experimental conditions, we performed RT-PCR
with RNA from HT-29 cells stimulated with TNF-K (10 ng/
ml; RpD Systems) for 3 and 6 h using primers recognizing
the CCL20 cDNA. The expression of CCL20 transcripts
was compared with that of IL-8, which is known to be in-
duced by pro-in£ammatory stimuli. Expression of both
CCL20 and IL-8 mRNA was induced by TNF-K in HT-29
cells (Fig. 4c).
EMSA analysis from nuclear extracts of TNF-K-stimulated
HT-29 cells showed a speci¢c complex binding to the NF-UB
binding site of the CCL20 promoter containing the NF-UB
subunits p50 and p65. This result further con¢rmed that
TNF-K induced activation of NF-UB in both cell lines tested,
which bound to its cognate site located in the CCL20 pro-
moter (Fig. 4d).
4. Discussion
Taken together, our results demonstrate the clear involve-
ment of NF-UB in regulation of CCL20 expression. Although
this NF-UB binding site represents a non-standard binding site
for NF-UB, a similar binding site has been shown to exist in
antisense orientation in the promoter of the mouse c-myc gene
[28].
Activation of the CCL20 promoter by TNF-K was 2.5^5-
fold lower than activation of the IL-8 promoter in G-361 cells.
In general, CCL20 expression has been shown to be 10^100-
fold lower than expression of IL-8 by di¡erent cell lines and
primary cells [19], which may be at least partially explained by
this di¡erence in promoter activation. However, when the
NF-UB binding site of the CCL20 promoter was replaced by
the IL-8 NF-UB binding site, no di¡erence in activation was
seen compared to the wild-type CCL20 promoter construct S6
(Fig. 2b), indicating that the di¡erence in response between
the CCL20 and the IL-8 promoter cannot be explained by a
di¡erence in the primary sequence of the NF-UB binding site,
Fig. 3. The minimal CCL20 promoter is activated by overexpression of p65 in HEK293 cells. a: HEK293 cells were transiently cotransfected
with the CCL20 promoter construct S6 (nt 3111 to +58) (dark gray bars) or S7 (nt 377 to +58) (light gray bars) together with either the
pcDNA3.1 vector or the p65 expression plasmid. The pRL-tk vector was used as internal control for transfection e⁄ciency. Fire£y luciferase
activities were normalized to renilla luciferase activities. Relative luciferase activities from p65-transfected cells compared to vector-transfected
cells are shown as means þ S.D. from four independent experiments. b: HEK293 cells were cotransfected with the construct tkLUC (white
bars) or 2U(CCL20)NF-UB tkLUC (black bars) together with either the pcDNA3.1 vector or the p65 expression plasmid. The pRL-tk vector
was used as internal control for transfection e⁄ciency. Fire£y luciferase activities were normalized to renilla luciferase activities. Relative lucif-
erase activities compared to vector-transfected cells are shown as means þ S.D. from four independent experiments.
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but may be due to a di¡erent promoter context or involve-
ment of sequences £anking the NF-UB binding site. Although
NF-UB can bind and activate the CCL20 promoter, it has yet
to be determined whether CCL20 regulation by pro-in£am-
matory cytokines occurs at the transcriptional level in other
cell systems. Nakayama et al. concluded that induction of
CCL20 expression by IL-1K in cultured human primary ker-
atinocytes is NF-UB-independent, since dexamethasone and
FK506 were unable to downregulate CCL20 expression in
these cells [18]. It is also likely that in some cell types pro-
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in£ammatory cytokines regulate CCL20 expression at the
post-transcriptional level. In this context, the 3P-untranslated
region of the CCL20 mRNA contains three copies of the
destabilization motif AUUUA, which is associated with rapid
mRNA degradation [4].
In this report we describe the cloning and characterization
of the promoter of the human CCL20 gene and demonstrated
its activation by NF-UB. Further analysis of the promoter
should help to gain more insight into the regulation of this
chemokine in di¡erent cell systems.
After initial submission of this manuscript, a publication by
Fujiie et al. appeared, showing the cloning of the mouse
LARC/MIP-3K/CCL20 promoter. The murine promoter con-
tains an NF-UB binding site with a sequence identical to the
human gene. Transfection of Caco-2 or HEK293 cells with a
promoter-luciferase construct and stimulation with the pro-
in£ammatory cytokines IL-1K or TNF-K identi¢ed this NF-
UB binding site as a key element in the regulation of this
promoter [29]. These data largely con¢rm our observations
on the human CCL20 promoter.
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Fig. 4. NF-UB binds to a site in the CCL20 promoter. a: EMSA was performed with 10 Wg of nuclear extracts from G-361 cells using a radio-
labelled oligonucleotide representing the NF-UB binding site of the CCL20 promoter. Left panel: binding activity in untreated cells (lane 1)
and G-361 cells treated with TNF-K for 4 h (lane 2); right panel: competition and supershift analysis from nuclear extracts of TNF-K-stimu-
lated G-361 cells; lane 3: competition with 100U molar excess of wild-type CCL20 NF-UB oligonucleotide; lane 4: competition with 100U
molar excess of mutated CCL20 NF-UB oligonucleotide; lane 5: competition with 100U molar excess of an oligonucleotide representing the
NF-UB binding site of the HIV LTR; lane 6: supershift with anti-p50; lane 7: supershift with anti-p65. b: EMSA was performed with 10 Wg
of nuclear extracts from G-361 cells using a radiolabelled oligonucleotide representing the NF-UB binding site of the HIV LTR. Left panel:
binding activity in untreated (lane 1) and G-361 cells treated with TNF-K for 1 h (lane 2); right panel: competition analysis using extracts
from TNF-K-stimulated G-361 cells; lane 3: competition with 100U molar excess of wild-type CCL20 NF-UB oligonucleotide; lane 4: competi-
tion with 100U molar excess of mutated CCL20 NF-UB oligonucleotide. c: RT-PCR analysis of CCL20, IL-8 and L-actin mRNA expression
in HT-29 cells (lane 1: untreated; lane 2: 3 h TNF-K ; lane 3: 6 h TNF-K). Ampli¢ed product size is 321 bp for CCL20, 291 bp for IL-8 and
434 bp for L-actin mRNA. d: EMSA was performed with 10 Wg of nuclear extracts from HT-29 cells using a radiolabelled oligonucleotide rep-
resenting the NF-UB binding site of the CCL20 promoter. Left panel: untreated HT-29 cells (lane 1), and HT-29 cells stimulated with TNF-K
for 4 h (lane 2); right panel: competition and supershift analysis from nuclear extracts of TNF-K-stimulated HT-29 cells; lane 3: competition
with 100U molar excess of wild-type CCL20 NF-UB oligonucleotide; lane 4: competition with 100U molar excess of mutated CCL20 NF-UB
oligonucleotide; lane 5: competition with 100U molar excess of an oligonucleotide representing the NF-UB binding site of the HIV LTR; lane
6: supershift with anti-p50; lane 7: supershift with anti-p65.
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